个人简介

M.D. (Doctor of Medicine) Ph.D. (Doctor of Philosophy)

研究领域

Molecular Biology and Disease

With his longtime collaborator Dr. Markus Eszlinger, Dr. Moosa Khalil and Dr. Sana Ghaznavi, he aims for a major change of clinical practice by solving the inherent limitations of fine needle aspiration cytology (FNAC). FNAC is unable to distinguish between benign and malignant follicular tumors in 20% of cases thus currently requiring 560 “diagnostic” surgeries in Alberta with malignancy found in only 20%. The molecular test devised by Dr. Eszlinger and Dr. Paschke could replace most if not all diagnostic surgeries for indeterminate FNACs by molecular testing of FNA material. This could allow allocation of these patients to either follow up for mutation and miRNA negative samples or primary total thyroidectomy for those samples that are mutation positive. Together with Dr. Chris Symonds (Chair of the Calgary thyroid tumour team) and colleagues from Endocrinology, Surgery, Pathology, Radiology, Medical and Radiation Oncology, Dr. Paschke is currently working towards the introduction of a multidisciplinary thyroid cancer clinic (MDTCC) in Calgary to provide a one stop, guideline-oriented and risk-stratified diagnosis, treatment and follow up for thyroid cancer patients. With Dr. Paula Seal (EFW) and Dr. Chris Symonds, Dr. Paschke is currently introducing standardised ultrasound malignancy risk stratification for thyroid nodules in Calgary which should identify 50% of thyroid nodules as benign. A “knock-in” transgenic mouse model of non-autoimmune hyperthyroidism (which was created by Dr. Holger Jäschke in the laboratory of Jukka Kero and Matti Poutamen in Turku/Finnland) and other transgenic mouse models will be transferred to Calgary to further support basic research on the pathogenesis of thyroid tumours in the laboratory of Drs. Paschke and Eszlinger at the Arnie Charbonneau Cancer Institute. Dr. Paschke is currently looking for MSc and PhD Graduate Students to join his laboratory.

近期论文

查看导师最新文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Calebiro D, Grassi ES, Eszlinger M, Ronchi CL, Godbole A, Bathon K, Guizzardi F, de Filippis T, Krohn K, Jaeschke H, Schwarzmayr T, Bircan R, Gozu HI, Sancak S, Niedziela M, Strom TM, Fassnacht M, Persani L, Paschke R 2016 Recurrent EZH1 mutations in autonomous thyroid adenomas J Clin Invest.126(9):3383-8. doi: 10.1172/JCI84894 Stokowy T, Wojtas B, Jarzab B, Krohn K, Fredman D, Dralle H, Musholt T, Hauptmann S, Lange D, Hegedüs L, Paschke R, and Eszlinger M 2016 Two-miRNA-classifiers differentiate mutation-negative follicular thyroid carcinomas and follicular thyroid adenomas in Fine Needle Aspirations with high specificity Endocrine 54(2):440-447 Krane JF, Cibas ES, Alexander EK, Paschke R, Eszlinger M 2015 Molecular Analysis of Residual ThinPrep Material from Thyroid FNAs Increases Diagnostic Sensitivity Cancer Cytopathology 123(6):356-61 Eszlinger M, Piana S, Moll A, Bosenberg E, Bisagni A, Ciarrocchi A, Ragazzi M, Paschke R 2015 Molecular testing of thyroid fine needle aspirations (FNA) improves pre-surgical diagnosis and supports the histological identification of minimally invasive follicular thyroid carcinomas. Thyroid 25(4):401-409 Jaeschke H, Schaarschmidt J, Eszlinger M, Huth S, Puttinger R, Rittinger O, Meiler J, Paschke R 2014 A newly discovered TSHR variant (L665F) associated with non-autoimmune hyperthyroidism in an Austrian family induces constitutive TSHR activation by steric repulsion between TM1 and TM7. J Clin Endocrinol Metab:jc20141436 Wojtas B, Ferraz C, Stokowy T, Hauptmann S, Lange D, Dralle H, Musholt T, Jarzab B, Paschke R, Eszlinger M 2014 Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. Mol Cell Endocrinol 388(1-2):1-9 Eszlinger M, Krogdahl A, Münz S, Rehfeld C, Precht Jensen EM, Ferraz C, Bösenberg E, Drieschner N, Scholz M, Hegedüs L, Paschke R. 2013 Impact of molecular screening for point mutations and rearrangements in routine air-dried Fine Needle Aspiration samples of thyroid nodules. Thyroid 24(2):305-13. Ferraz C, Lorenz S, Wojtas B, Bornstein SR, Paschke R & Eszlinger M. 2013 Inverse Correlation of miRNA and Cell Cycle-Associated Genes Suggests Influence of miRNA on Benign Thyroid Nodule Tumorigenesis. J Clin Endocrinol Metab 98(1) E8-E16. Ferraz C, Rehfeld C, Krogdahl A, Jensen EMP, Bosenberg E, Narz F, Hegedus L, Paschke R & Eszlinger M. 2012 Detection of PAX8/PPARG and RET/PTC Rearrangements Is Feasible in Routine Air-Dried Fine Needle Aspiration Smears. Thyroid 22 1025-1030. Ferraz C, Eszlinger M & Paschke R. 2011 Current State and Future Perspective of Molecular Diagnosis of Fine-Needle Aspiration Biopsy of Thyroid Nodules. Journal of Clinical Endocrinology & Metabolism 96 2016-2026. Eszlinger M, Krohn K, Kukulska A, Jarzab B & Paschke R. 2007 Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors. Endocrine Reviews 28 322-338. Eszlinger M, Krohn K, Berger K, Lauter J, Kropf S, Beck M, Fuhrer D & Paschke R. 2005 Gene expression analysis reveals evidence for increased expression of cell cycle-associated genes and G(q)-protein-protein kinase C signaling in cold thyroid nodules. Journal of Clinical Endocrinology & Metabolism 90 1163-1170. Eszlinger M, Krohn K, Frenzel R, Kropf S, Tonjes A & Paschke R. 2004 Gene expression analysis reveals evidence for inactivation of the TGF-beta signaling cascade in autonomously functioning thyroid nodules. Oncogene 23 795-804.